|
Aug 26
|
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
|
|
Aug 26
|
Roche to increase global laboratory capacity for mpox testing
|
|
Jul 29
|
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
|
|
Jul 29
|
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
|
|
Jul 29
|
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
|
|
Jul 29
|
Roche acquires Point of Care technology from LumiraDx
|
|
Jul 29
|
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
|
|
Jul 26
|
Roche records 4% decline in H1 2024 net income
|
|
Jul 25
|
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
|
|
Jul 25
|
Health Care Roundup: Market Talk
|
|
Jul 25
|
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
|
|
Jul 25
|
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
|
|
Jul 25
|
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
|
|
Jul 25
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
|
|
Jul 23
|
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
|
|
Jun 17
|
Roche’s Columvi shows to offer extended survival in Phase III DLBCL trial
|
|
Jun 17
|
EHA 2024: Roche’s Columvi competes in BiTE battle with positive results in DLBCL
|
|
Jun 15
|
Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
|
|
Jun 15
|
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
|
Jun 10
|
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
|